Clinical Trial Update: D2C7-IT With Atezolizumab for Recurrent Gliomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of D2C7-IT in combination with atezolizumab for recurrent malignant glioma; study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Atezolizumab (atezolizumab)
• D2C7-IT

Snippet

Sponsor: Darell Bigner | Conditions: Malignant Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING